Papers/PMID:39042390
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society2024The record
1 finding drawn from this paper, on 1 compound across 1 endpoint.
What it reported
How to read these marksWhat moved
1 finding
berberine — decreases alanine aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×1“After a 12-week intervention, the BBR group demonstrated a statistically significant decrease in alanine transaminase (ALT) p=0.0105, and de Ritis ratio p=0.0011 compared to the control group.”
Quoted verbatim from Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- berberine 1500 mg/day, oral, 12 weeks
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD)